XO Life

Medikura is now XO Life!

The Real World Evidence Platform for Drug Effectiveness and Safety.
210616 Exposé MEDIKURA_DE

XO Life (Medikura) Investment Exposé

Share your email address with us to receive investment information

Quick Facts

Frame 4
Frame 2 (1)
Frame 3
Germany-1.png
Investment-Typ: Subordinated Loan

Venture Category

Digital Health

Financing Round

Pre-Series A

Business Phase
Market Entry
Investment Offer

Funding Target

€ 2 m

Term

31.12.2026

Pre-Money Valuation

€ 9 m

Investor Yield

1,0 % p.a. base interest + revenue share

Legal warning: The acquisition of this investment is associated with considerable risks and may lead to the complete loss of the invested assets. The promised return is not guaranteed and may also be lower.

Overview

The Trip Advisor for medicines with a scientifically validated data concept behind it.

XO Life is on its way to becoming the leading Real World Evidence (RWE) platform based on standardized patient reports in Germany and aims to capture millions of treatment data.

Recognized and honored

Unparalleled partner network, e.g. the leading national research institute for patient-centered research at Charité and publishers such as Wort & Bild (ApothekenUmschau) and other publishing houses.

XO Life has also been awarded several prizes and € 250,000 in funding on European level (EIC SME Instrument), German federal level (EXIST) and Bavarian state level.

Patients, medical staff und pharma

Together with its partners, XO Life is rolling out RWE’s leading platform for patient feedback across indications, offering:

  • Patients & medical staff: better treatment monitoring and individualized treatment.
  • Pharma: real insights into treatment satisfaction based on patient feedback; more cost-efficient & targeted R&D

What makes XO Life unique?

Reliable: Three years of platform operation in a highly sensitive environment, audited processes and compliance with legal guidelines.

Scalable: Real-world evidence database and platform technology as a hub for multiple applications and use cases.

Valuable: Establishment of a unique, pseudonymized database as the basis for precision medicine.

Key Highlights

Patient-Centered Services

  • medwatcher.io is set to become the largest RWE platform, enabling patients to provide feedback on their care, compare themselves to other patients and receive updates about their treatment

  • Partnerships with major publishers

RWE-Data-Validation

  • XO Life RWE database as a decision-making tool for life science companies, medical providers, insurers and other healthcare stakeholders

  • Partnership with world leader in health information technology

Digital treatment monitoring app

  • Scalable, standardized and indication-independent web app for patient treatment monitoring
  • Partnerships with pharmaceutical companies and clinics

  • Digital patient engagement to increase adherence and improve customer loyalty

PV case management software​

  • Software solution for pharmaceutical companies to facilitate safety case processing

  • Secure communication infrastructure between pharma and patients

  • Partnerships with medium-sized pharmaceutical companies

Team

A Multidiciplinary Team

 Entrepreneurs with excellent track records, accompanied by a scientific advisory board of leading European researchers.

Dr. Friderike Bruchmann
CEO

Dr. Friderike brings an entrepreneurial spirit, a good understanding of tech, and an impressive resumé to the start-up. 

Scott Weiss
CPO

Product and design is Scott’s world. He’s already helped several startups make it to the top.

Johannes Bachhuber
CTO

Johannes is the brain behind XO Life – from Web Developer to Technical Lead. He has already gained a lot of valuable experience. 

Dr. med. Maria Lutz
Head of Medical Affairs

With Maria, XO Life has an excellent expert with years of experience in the medical field on board.

Beirat

Dr. Burkhard Breuer
CEO ProInnovera
Benjamin Luther
MediVentures / MEDICE
Dr. Dennis Ballwieser
MD Wort & Bild Verlag (ApothekenUmschau)
Prof. Joerg Hasford (†)
Medizinische Datenverarbeitung, LMU

Downloads

Edit

XO Life (Medikura) Investment Exposé

Share your email address with us to receive investment information

Contact

XO Life GmbH Contact & Legal notice

XO Life GmbH
Agnes-Pockels-Bogen 1
80992 München
Deutschland

Commercial Register: HRB 238648
Registered Office: München
Year of incorporation: 2018
Managing Director: Dr. Friderike Bruchmann

Notice under § 12 (2) & (3) of the German Investment Act (Vermögensanlagengesetz)

The acquisition of this investment is associated with considerable risks and may lead to the complete loss of the invested assets. The promised return is not guaranteed and may also be lower. aescuvest GmbH does not guarantee that reported interest will actually be achieved.

More information can be found under risk information.

image001

Download all investment information of XO Life now!

XO Life (Medikura) Investment Exposé

Share your email address with us to receive investment information